Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine
https://www.jnj.com/johnson-johnson-announces-european-commission-approval-for-janssens-preventive-ebola-vaccine
Johnson & Johnson Receives Positive CHMP Opinion for Janssen's Investigational Preventive Ebola Vaccine Regimen
https://www.jnj.com/johnson-johnson-receives-positive-chmp-opinion-for-janssens-investigational-preventive-ebola-vaccine-regimen (29 May 2020)
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak,
https://www.jnj.com/johnson-johnson-announces-commitmentto-support-republic-of-rwandas-preparedness-against-ebolaoutbreak (8 December 2019)
Johnson & Johnson Announces Donation of up to 500,000
Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC),
https://www.jnj.com/johnson-johnson-announces-donation-of-upto-500-000-regimens-of-janssens-investigational-ebola-vaccineto- support-outbreak-response-in-democratic-republic-of-thecongo-drc (31 October 2019)
19/12/2015: First encouraging results for EBOVAC on Ebola Vaccine Regimen
The clinical data analysis shows very encouraging results with an antibody response produced by the prime-boost Ebola vaccine regimen in 100 percent of healthy volunteers that was sustained 8 months following immunization.
View press release here.
08/12/2015: Inserm has launched its campaign to enrol 300 volunteers for Phase 2 trials.
View press release here.
15/07/2015: The University of Oxford has started enrolling volunteers for Phase 2 trials.
View press release here.
16/01/2015: IMI2: First innovative medicines Initiative Ebola projects get underway:
http://www.imi.europa.eu/content/press-releases
